New pill could help kidneys last longer
NCT ID NCT07419828
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether HRS-1780 tablets can slow the decline of kidney function in nearly 2,000 adults with chronic kidney disease. Participants take the drug or a placebo alongside standard treatment. The study will track kidney health over 32 months to see if the drug helps preserve kidney function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HRS-1780 tablets
- What this could lead to
- If successful, HRS-1780 could offer a new way to slow kidney function loss in people with chronic kidney disease, potentially delaying the need for dialysis or transplant.
- What could go wrong
- This is a large Phase 3 trial, but the drug is still experimental. It may not prove better than standard care, and side effects are possible. Results are not expected for over two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 5,386 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
May 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female, aged ≥18 and \<80 years old on the day of signing the informed consent form; * a) The estimated glomerular filtration rate calculated by the CKD-EPI 2009 formula of the Chronic Kidney Disease Epidemiology Collaboration was eGFR≥60 and \<90 mL/min/1.73 m2, and UACR≥300 mg/g; Or b) eGFR≥30 and \<60 mL/min/1.73 m2, and UACR≥30 mg/g ; Or c) eGFR≥25 and \<30 mL/min/1.73 m2; * Serum potassium ≤4.8 mmol/L * HbA1c was less than 10.5%. Exclusion Criteria: * Uncontrolled severe hypertension at the time of screening or randomization (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); * Alanine aminotransferase (ALT) \>3× upper limit of normal (ULN); Aspartate aminotransferase (AST) \>3×ULN; Total bilirubin \>2.0×ULN; * Diagnosis or suspicion of polycystic kidney disease, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis; Acute kidney injury occurred within 90 days before screening or hemodialysis or peritoneal dialysis treatment was received; * Have received a kidney transplant in the past or plan to receive a kidney transplant during the trial period; * There are diseases that may cause hyperkalemia during screening or randomization (such as Addison's disease); * Within 180 days prior to the screening, the participants had the following diseases of clinical significance, which, as determined by the investigators, might interfere with the trial results or pose additional risks to the administration of the study drug: including but not limited to respiratory system, digestive system, cardiovascular and cerebrovascular, endocrine, immune, urinary, adrenal, blood, nervous, mental and other diseases; * Stroke, transient ischemic attack, myocardial infarction, coronary revascularization, and decompensated heart failure (NYHA grade III-IV) occurred within 90 days before screening. And/or planned to undergo coronary, carotid or peripheral artery revascularization at the time of screening
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
RECRUITINGNanjing, Jiangsu, 210002, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Investigation of pharmacokinetics of a single subcutaneous dose of NNC0537-1482 in participants with various degrees of renal function
- Can a gentle electric pulse train the breathing muscle in COPD?
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Family talks may ease the toll of kidney dialysis
- A finger prick instead of a needle: could At-Home blood tests match hospital accuracy?
- Can a daily capsule tame dangerous phosphorus levels in dialysis patients?